DMAC
Price
$6.14
Change
+$0.77 (+14.34%)
Updated
Sep 5 closing price
Capitalization
317.37M
60 days until earnings call
EDIT
Price
$2.76
Change
+$0.24 (+9.52%)
Updated
Sep 5 closing price
Capitalization
248.18M
65 days until earnings call
Interact to see
Advertisement

DMAC vs EDIT

Header iconDMAC vs EDIT Comparison
Open Charts DMAC vs EDITBanner chart's image
DiaMedica Therapeutics
Price$6.14
Change+$0.77 (+14.34%)
Volume$754.56K
Capitalization317.37M
Editas Medicine
Price$2.76
Change+$0.24 (+9.52%)
Volume$2M
Capitalization248.18M
DMAC vs EDIT Comparison Chart in %
Loading...
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DMAC vs. EDIT commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMAC is a Hold and EDIT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (DMAC: $6.14 vs. EDIT: $2.76)
Brand notoriety: DMAC and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMAC: 205% vs. EDIT: 90%
Market capitalization -- DMAC: $317.37M vs. EDIT: $248.18M
DMAC [@Biotechnology] is valued at $317.37M. EDIT’s [@Biotechnology] market capitalization is $248.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMAC’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 0 green FA rating(s).

  • DMAC’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 0 green, 5 red.
According to our system of comparison, EDIT is a better buy in the long-term than DMAC.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMAC’s TA Score shows that 5 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • DMAC’s TA Score: 5 bullish, 3 bearish.
  • EDIT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, DMAC is a better buy in the short-term than EDIT.

Price Growth

DMAC (@Biotechnology) experienced а +7.53% price change this week, while EDIT (@Biotechnology) price change was +7.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

Reported Earning Dates

DMAC is expected to report earnings on Nov 05, 2025.

EDIT is expected to report earnings on Nov 10, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMAC($317M) has a higher market cap than EDIT($248M). EDIT YTD gains are higher at: 117.323 vs. DMAC (13.076). DMAC has higher annual earnings (EBITDA): -31.42M vs. EDIT (-227.72M). EDIT has more cash in the bank: 179M vs. DMAC (30M). DMAC has less debt than EDIT: DMAC (292K) vs EDIT (21.1M). EDIT has higher revenues than DMAC: EDIT (38.9M) vs DMAC (0).
DMACEDITDMAC / EDIT
Capitalization317M248M128%
EBITDA-31.42M-227.72M14%
Gain YTD13.076117.32311%
P/E RatioN/AN/A-
Revenue038.9M-
Total Cash30M179M17%
Total Debt292K21.1M1%
FUNDAMENTALS RATINGS
DMAC vs EDIT: Fundamental Ratings
DMAC
EDIT
OUTLOOK RATING
1..100
7973
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
63
Fair valued
PROFIT vs RISK RATING
1..100
95100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
4247
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (63) in the Biotechnology industry is in the same range as DMAC (68). This means that EDIT’s stock grew similarly to DMAC’s over the last 12 months.

DMAC's Profit vs Risk Rating (95) in the Biotechnology industry is in the same range as EDIT (100). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

DMAC's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (100). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

DMAC's Price Growth Rating (42) in the Biotechnology industry is in the same range as EDIT (47). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

DMAC's P/E Growth Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that DMAC’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMACEDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
72%
MACD
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 4 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 2 days ago
66%
View a ticker or compare two or three
Interact to see
Advertisement
DMAC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OJOC335.000.50
+0.15%
Ojai Oil Co.
PPCCY58.250.02
+0.03%
PICC Property and Casualty Co., Ltd.
HKSHF0.71N/A
N/A
Hong Kong & Shanghai Hotels
NXPRF149.16N/A
N/A
Nexans Paris ACT
CCUR2500.00N/A
N/A
CCUR Holdings, Inc.

DMAC and

Correlation & Price change

A.I.dvisor indicates that over the last year, DMAC has been loosely correlated with WHWK. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if DMAC jumps, then WHWK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DMAC
1D Price
Change %
DMAC100%
+14.34%
WHWK - DMAC
47%
Loosely correlated
+0.55%
ARCT - DMAC
38%
Loosely correlated
+6.50%
HUMA - DMAC
35%
Loosely correlated
-2.05%
LQDA - DMAC
32%
Poorly correlated
+0.03%
EDIT - DMAC
31%
Poorly correlated
+9.52%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with AXON. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+9.52%
AXON - EDIT
52%
Loosely correlated
-0.24%
CRSP - EDIT
50%
Loosely correlated
+4.02%
VCYT - EDIT
49%
Loosely correlated
+2.89%
ARRY - EDIT
47%
Loosely correlated
-1.32%
NTLA - EDIT
47%
Loosely correlated
+3.79%
More